Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. OGX-011 may help docetaxel and prednisone kill more tumor cells by making tumor cells less resistant to the drugs. PURPOSE: This randomized phase II trial is studying how well giving docetaxel and prednisone with or without OGX-011 works in treating patients with recurrent or metastatic prostate cancer that did not respond to previous hormone therapy.

Key facts

Study ID

NCT00258388

Run by

NCIC Clinical Trials Group

People needed

82

Starts

2005-09-28

Expected to finish

2011-01-18

Last updated by the study team

2023-08-04

Who can join

Age: 18 and older, up to 120. Sex: male. Healthy volunteers: not accepted.

Where it is running

• University of Washington — Seattle, Washington, United States
• Tom Baker Cancer Centre — Calgary, Canada
• Cross Cancer Institute — Edmonton, Canada
• QEII Health Sciences Center — Halifax, Canada
• Juravinski Cancer Centre at Hamilton Health Sciences — Hamilton, Canada
• BCCA - Cancer Centre for the Southern Interior — Kelowna, Canada
• London Regional Cancer Program — London, Canada
• CHUM - Hopital Notre-Dame — Montreal, Canada
• Atlantic Health Sciences Corporation — Saint John, Canada
• Odette Cancer Centre — Toronto, Canada
• Univ. Health Network-Princess Margaret Hospital — Toronto, Canada
• BCCA - Vancouver Cancer Centre — Vancouver, Canada
• CancerCare Manitoba — Winnipeg, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.